The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Analysts at Leerink Partnrs boosted their Q4 2024 EPS estimates for Bristol-Myers Squibb in a report released on Sunday, ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

The root of the problem was a fire caused by a cooling system water pipe leak at a data center in Paris, used by the company ...

UBS analyst Graham Doyle maintained a Buy rating on ConvaTec (CTEC – Research Report) today and set a price target of p360.00. The company’s ...

Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment ...

Of the $3.2 trillion in deals closed last year globally, the healthcare sector accounted for only 8%, with M&A partially ...

Known for its sumptuous flavor and extravagant price, wagyu beef is tops when it comes to red meat, with only the best cuts ...

Shares of The First Bancshares, Inc. (NASDAQ:FBMS – Get Free Report) have received an average recommendation of “Moderate Buy” from the four analysts that are presently covering the firm, Marketbeat ...